Biomarker Menu


Download this assay page in pdf format.


CICP (PICP) (C-Propeptide of Type I Procollagen)

Analyte: C-Propeptide of Type I Procollagen

Specimen Type: Serum

Optimum Volume: 0.5 mL


2-8°C -20°C -70°C
5 days 26 days 2 years

Reporting units: ng/mL

Method: EIA

Biological or Clinical Significance:

Type 1 Collagen is a primary organic constituent of bone. The release of these peptides into the circulation as the result of the cleavage of type I collagen (CICP) provides a stoichiometric representation of the production of collagen.

Type I collagen levels have been linked to bone growth and formation. Levels of CICP are indicative of collagen production in vivo. Elevated levels of CICP have been shown in diseases associated with high levels of bone turnover, including Paget’s disease (see reference 1), hyperthyroidism, primary hyperparathyroidism and renal osteodystrophy. Slightly elevated levels of CICP have also been documented in some women in early menopause (see reference 2).

Principle of Test Method:

The CICP assay is a solid-phase ELISA designed to measure human CICP in serum and plasma. It employs the quantitative sandwich enzyme immunoassay principle.


1, Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget’s disease of bone. J Clin Endocrinol Metab. 1984; 58:110-120.
2. Ebeling PR, Atley LM, Guthrie JR, Durger HG, Dennerstein L, Hopper JL, Wark JD. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 1996; 81:3366-3371.

Related Assays

Downloadable, Printable Biomarker Menus

Alphabetical Listing

Download PDF

Biomarker Category

Download PDF